- Home
- SKYE
as 11-22-2024 4:00pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 108.3M | IPO Year: | N/A |
| Target Price: | $18.67 | AVG Volume (30 days): | 166.3K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $19.41 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Skye Bioscience Inc. Common Stock (SKYE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | SKYE | Chief Development Officer | Nov 15 '24 | Sell | $5.27 | 19,574 | $97,721.86 | 101,748 | |
| ARSENAULT KAITLYN | SKYE | Chief Financial Officer | Nov 15 '24 | Sell | $5.27 | 43,396 | $216,652.44 | 166,342 | |
| 5AM Partners VII, LLC | SKYE | 10% Owner | Sep 11 '24 | Sell | $6.33 | 266,337 | $1,750,352.22 | 66,356 | |
| Schwab Andrew J. | SKYE | Director10% Owner | Sep 11 '24 | Sell | $6.33 | 266,337 | $1,750,352.22 | 8,167,206 |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
TipRanks
8 days ago
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
GlobeNewswire
9 days ago
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
GlobeNewswire
16 days ago
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
19 days ago
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
GlobeNewswire
22 days ago
Skye Bioscience to Announce Third Quarter 2024 Results
GlobeNewswire
25 days ago
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
GlobeNewswire
a month ago
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Compare SKYE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.